InVitae Corp (NASDAQ:NVTA) has been assigned an average rating of “Hold” from the seven brokerages that are presently covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $15.00.

Several analysts have recently issued reports on the company. BidaskClub downgraded InVitae Corp from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Zacks Investment Research downgraded InVitae Corp from a “hold” rating to a “sell” rating in a research report on Tuesday, July 18th. Finally, ValuEngine upgraded InVitae Corp from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd.

COPYRIGHT VIOLATION WARNING: This story was first reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/08/08/invitae-corp-nvta-receives-consensus-recommendation-of-hold-from-analysts.html.

Shares of InVitae Corp (NASDAQ:NVTA) traded down 8.79% during trading on Tuesday, reaching $9.23. 763,479 shares of the company traded hands. The company’s market capitalization is $390.56 million. The stock’s 50 day moving average is $9.49 and its 200 day moving average is $9.75. InVitae Corp has a 1-year low of $5.76 and a 1-year high of $11.88.

InVitae Corp (NASDAQ:NVTA) last issued its quarterly earnings data on Monday, August 7th. The medical research company reported ($0.66) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by $0.02. InVitae Corp had a negative net margin of 260.48% and a negative return on equity of 119.10%. The company had revenue of $14.34 million during the quarter, compared to analysts’ expectations of $13.31 million. During the same quarter in the prior year, the company earned ($0.77) earnings per share. The firm’s revenue was up 157.0% compared to the same quarter last year. On average, analysts forecast that InVitae Corp will post ($2.42) EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in NVTA. Nationwide Fund Advisors raised its position in InVitae Corp by 21.1% in the first quarter. Nationwide Fund Advisors now owns 17,121 shares of the medical research company’s stock valued at $189,000 after buying an additional 2,987 shares during the last quarter. Donald L. Hagan LLC raised its position in InVitae Corp by 30.0% in the second quarter. Donald L. Hagan LLC now owns 13,000 shares of the medical research company’s stock valued at $124,000 after buying an additional 3,000 shares during the last quarter. American International Group Inc. raised its position in InVitae Corp by 31.3% in the first quarter. American International Group Inc. now owns 17,174 shares of the medical research company’s stock valued at $190,000 after buying an additional 4,090 shares during the last quarter. Credit Suisse AG raised its position in InVitae Corp by 22.9% in the first quarter. Credit Suisse AG now owns 25,178 shares of the medical research company’s stock valued at $279,000 after buying an additional 4,694 shares during the last quarter. Finally, Teachers Advisors LLC raised its position in InVitae Corp by 18.3% in the fourth quarter. Teachers Advisors LLC now owns 42,372 shares of the medical research company’s stock valued at $336,000 after buying an additional 6,547 shares during the last quarter.

InVitae Corp Company Profile

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with MarketBeat.com's FREE daily email newsletter.